| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16078 R66722 |
Christensen (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2024 | Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
1.39 [1.16;1.65] excluded (control group) |
341/2,669 546/5,299 | 887 | 2,669 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16020 R66503 |
Christensen (Carbamazepine) (Epilepsy) (Controls unexposed, general population), 2024 | Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.27 [1.11;1.47] | 341/2,669 2,416/22,227 | 2,757 | 2,669 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15365 R63209 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.28 [0.03;2.20] C excluded (control group) |
1/27 13/106 | 14 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15366 R63222 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.20 [0.02;1.59] C | 1/27 13/80 | 14 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8082 R24680 |
Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.60 [0.11;62.58] C excluded (control group) |
2/15 0/7 | 2 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8074 R24628 |
Aydin (Carbamazepine) (Controls unexposed, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 8.60 [0.38;193.87] C | 2/15 0/22 | 2 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8145 R25041 |
Cohen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2019 | Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) | early pregnancy | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.35 [0.51;3.61] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8141 R25013 |
Cohen (Carbamazepine) (Controls unexposed NOS), 2019 | Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) | early pregnancy | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 0.71 [0.35;1.43] | -/- 41,653/1,440,631 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6356 R21030 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | Small for gestational age (SGA) birth weight | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
3.04 [0.97;9.51] C excluded (control group) |
9/67 5/103 | 14 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6354 R17339 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | Small for gestational age (SGA) birth weight | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: Yes |
2.40 [1.20;4.90] excluded (control group) |
9/67 8,017/106,899 | 8,026 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6355 R17335 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | Small for gestational age (SGA) birth weight | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.78 [0.80;3.92] C | 9/67 31/386 | 40 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5511 R17485 |
Pennell (Carbamazepine), 2012 | Small for gestational age (SGA) (at birth) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 3.14 [0.91;10.90] | 12/93 4/98 | 16 | 93 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6621 R18188 |
Burja (Carbamazepine) (Controls unexposed, disease free), 2006 | Small for date (NOS) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No |
1.53 [0.41;5.66] C excluded (control group) |
3/19 23/211 | 26 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5591 R18142 |
Burja (Carbamazepine) (Controls unexposed, sick), 2006 | Small for date (NOS) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 5.81 [0.56;60.48] C | 3/19 1/32 | 4 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8220 R25718 |
Endo (Carbamazepine) (Controls unexposed, disease free), 2004 | Intrauterine growth retardation (NOS) | throughout pregnancy | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
2.61 [0.31;21.85] C excluded (control group) |
1/8 34/656 | 35 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8223 R25763 |
Endo (Carbamazepine) (Controls unexposed, sick), 2004 | Intrauterine growth retardation (NOS) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.23 [0.00;17.06] C | 1/8 0/1 | 1 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6298 R17069 |
Wide (Carbamazepine), 2000 | Small for gestationnal age | throughout pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 0.95 [0.02;49.04] C | 0/39 0/37 | 0 | 39 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 9 studies | 1.29 [0.84;2.00] | 2,834 | 2,937 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Epilepsy) (Controls unexposed, general population; 2: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Controls unexposed NOS; 5: Carbamazepine) (Controls unexposed, sick) ; 6: Carbamazepine; 7: Carbamazepine) (Controls unexposed, sick; 8: Carbamazepine) (Controls unexposed, sick; 9: Carbamazepine;
Asymetry test p-value = 0.8838 (by Egger's regression)
slope=0.2279 (0.1076); intercept=0.0794 (0.5242); t=0.1515; p=0.8838
excluded 8220, 6621, 6356, 6354, 8145, 8082, 15365, 16078